The discovery of BI-1 as a target for ICT has significant implications for the development and application of ICT-related drugs, and specifically, the ICT PROTACs, with LJ-41 as a prominent example, may serve as promising candidates for Burkitt lymphoma treatment. Here, TMBIM6 is linked to Burkitt lymphoma.